öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£ºÌÀÓÐÖ¾
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º85

ËùÊôԺУ£º»ªÄÏÅ©Òµ´óѧ
ËùÊôԺϵ£ºÊÞҽѧԺ
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼/²©µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º»ù´¡ÊÞҽѧ¡¢ÊÞÒ½¡¢ÊÞÒ½£¨·ÇÈ«ÈÕÖÆ£©¡¢ÊÞҽҩѧ
Ñо¿ÁìÓò£º Ò©ÎïºÏ³É¡¢·Ö×ÓÒ©Àíѧ
Ñо¿ÁìÓò£º Ò©ÎïºÏ³É¡¢·Ö×ÓÒ©Àíѧ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºyouzhitang@scau.edu.cn
ͨѶµØÖ·£º¹ãÖÝÊÐÌìºÓÇøÎåɽ·483ºÅ


¸öÈ˼òÊö :
¸öÈ˼ò½é
ÌÀÓÐÖ¾£¬ÄУ¬ºþ±±ºéºþÈË£¬1983Äê6Ô³öÉú£¬¸±½ÌÊÚ¡¢²©Ê¿¡¢»ù´¡ÊÞҽѧ£¨ÊÞÒ½Ò©ÀíÓ붾Àíѧ·½Ïò£©Ë¶Ê¿Éúµ¼Ê¦£¬ÏÖÈÎÊÞҽѧԺÊÞÒ½Ò©ÀíѧÓ붾Àíѧ½ÌÑÐÊÒÖ÷ÈΡ£2004Ä꼪ÁÖ´óѧ¸ß·Ö×Ó²ÄÁÏÓ빤³ÌöλÔÓéÀֵǼÈë¿ÚÏÂÔر¾¿Æ±ÏÒµ£¬2009Ä꼪ÁÖ´óѧ»ñÓлú»¯Ñ§²©Ê¿Ñ§Î»£¬Í¬Äê¾ÍÖ°ÓÚ»ªÄÏÅ©Òµ´óѧÊÞҽѧԺ£¬´ÓÊ¿¹Ñס¢¿¹¾úÐÂÊÞÒ©µÄÉè¼Æ¡¢ºÏ³É¼°×÷ÓûúÖÆÑо¿£¬2014Äê½úÉýΪ¸±½ÌÊÚ¡£ÏÖΪÖйúÐóÄÁÊÞҽѧ»áÊÞÒ½Ò©Àí¶¾Àíѧ·Ö»áÀíÊ¡£
»ñ½±ÈÙÓþ
2011ÄêÈëÑ¡¡°»ªÄÏÅ©Òµ´óѧ¹Ç¸ÉÇàÄê½Ìʦ¡±£¬2012ÄêÈëÑ¡»ªÄÏÅ©Òµ´óѧ¹ã¶«Ê¡¸ßµÈѧУ¡°Ç§°ÙÊ®¹¤³Ì¡±µÚÆßÅúУ¼¶ÅàÑø¶ÔÏó£¬2014ÄêÈëÑ¡¹ãÖÝÊÐÖé½­¿Æ¼¼ÐÂÐÇ£¬2014Äê»ñ¹ã¶«Ê¡¿Æѧ¼¼Êõ½±Ò»µÈ½±(13)¡£

¿ÆÑй¤×÷ :
¹¤×÷¾­Àú
2017Äê2ÔÂÖÁ½ñ£¬»ªÄÏÅ©Òµ´óѧ£¬ÊÞҽѧԺ£¬ÇàÄê½ÌÊÚ
2014Äê5ÔÂ-2015Äê9Ô£¬¼ÓÖÝ´óѧ¾É½ðɽ·ÖУ£¬Ò©Ñ§Ôº£¬·ÃÎÊѧÕß
2013Äê12ÔÂÖÁ½ñ£¬»ªÄÏÅ©Òµ´óѧ£¬ÊÞҽѧԺ£¬¸±½ÌÊÚ
2009Äê7ÔÂ-2013Äê12Ô£¬»ªÄÏÅ©Òµ´óѧ£¬ÊÞҽѧԺ£¬½²Ê¦
Éç»á¡¢Ñ§»á¼°Ñ§Êõ¼æÖ°
ÖйúÐóÄÁÊÞҽѧ»áÊÞÒ½Ò©Àí¶¾Àíѧ·Ö»áÀíÊÂ
¿ÆÑÐÏîÄ¿
Ö÷³Ö¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿¡¢ÇàÄê»ù½ð(Åú×¼ºÅ£º**¡¢**)¡¢¹ú¼ÒÖصãÑз¢¼Æ»®×Ó¿ÎÌâ(2016YFD**)¡¢½ÌÓý²¿²©Ê¿µãнÌʦ»ù½ð(Åú×¼ºÅ£º**013)¡¢¹ã¶«¸ßУÓÅÐãÇàÄê´´ÐÂÈ˲ÅÅàÓýÏîÄ¿(ÓýÃ繤³Ì)(Åú×¼ºÅ£ºLYM09032)¡¢¹ãÖÝÊÐÖé½­¿Æ¼¼ÐÂÐÇÏîÄ¿(Åú×¼ºÅ£º2014J**)¡¢»ªÄÏÅ©Òµ´óѧУ³¤»ù½ð(Åú×¼ºÅ£º5500-K11046)¡£
·¢±íÂÛÎÄ
[1]ZhenJin,Yao-ZhiYang,Jian-XinChen*,You-ZhiTang*¡°Inhibitionofpro-inflammatorymediatorsinRAW264.7cellsby7-Hydroxyflavoneand7,8-Dihydroxyflavone¡±JournalofPharmacyandPharmacology,2017,69(7):865-874.(DOI:10.1111/jphp.12714)
[2]Mei-LingGao,JieZeng,XiFang,JianLuo,ZhenJin,Ya-HongLiu,You-ZhiTang*¡°Design,synthesisandantibacterialevaluationofnovelpleuromutilinderivativespossessingpiperazinelinker¡±EuropeanJournalofMedicinalChemistry,2017,127:286-295.(DOI:10.1016/j.ejmech.2017.01.004)
[3]NilgunIsikReed,You-ZhiTang,JoelMcIntosh,YibingWu,KathleenS.Molnar,AnnafeliciaCivitavecchia,DeanSheppard,WilliamF.DeGrado,HyunilJo¡°ExploringN-Arylsulfonyl-l-prolineScaffoldasaPlatformforPotentandSelective¦Áv¦Â1IntegrinInhibitors¡±ACSMed.Chem.Lett.,2016,7(10):902-907.(DOI:10.1021/acsmedchemlett.6b00196).
[4]JianLuo,Qiu-EYang,Yuan-YuanYang,You-ZhiTang*,Ya-HongLiu*¡°Design,synthesisandstructure-activityrelationshipstudiesofnovelpleuromutilinderivativeshavingapiperazinering¡±ChemicalBiology&DrugDesign,2016,88(5):699-709.(DOI:10.1111/cbdd.12799).
[5]Yao-ZhiYang,You-ZhiTang*,Ya-HongLiu*¡°Wogonosidedisplaysanti-inflammatoryeffectsthroughmodulatinginflammatorymediatorexpressionusingRAW264.7cells¡±JournalofEthnopharmacology,148(1):271-276,2013.
[6]You-ZhiTang*,JianLuo,XiaojieChen,BoWang,XiangguangShen,JianhuaLiu*¡°Synthesisandinvitroantibacterialactivityoffournovelpleuromutilinderivatives¡±JournalofTheChileanChemicalSociety,58(1):1415-1418,2013.
[7]You-ZhiTang*,Ya-HongLiu*,Jian-XinChen¡°Pleuromutilinanditsderivatives-Theleadcompoundsfornovelantibiotics¡±MiniReviewsinMedicinalChemistry,12(1)£¬53-61,2012.
[8]Li-GuoYuan,You-ZhiTang,Y-XZhang,JianSun,Xian-YangLuo,Li-XiangZhu,ZhanZhang,RuiWang,Ya-HongLiu*.¡°DosageassessmentofvalnemulininpigsbasedonpopulationpharmacokineticandMonteCarlosimulation¡±JournalofVeterinaryPharmacologyandTherapeutics2015:38(4)400-409.
[9]Yun-YunYang,You-ZhiTang,Chun-LinFan,Hui-TaiLuo,Peng-RanGuo,Jian-XinChen¡°IdentificationanddeterminationofthesaikosaponinsinRadixbupleuribyacceleratedsolventextractioncombinedwithrapid-resolutionLC-MS¡±JournalofSeparationScience,33(13),1933-1945,2010.
[10]Dong-PingZeng,Xiang-GuangShen,Li-MinHe,Huan-ZhongDing,You-ZhiTang,Yong-XueSun,Bing-HuFang,Zhen-LingZeng¡°Liquidchromatographytandemmassspectrometryforthesimultaneousdeterminationofmequindoxanditsmetabolitesinporcinetissues¡±JournalofSeparationScience,35(10-11),1327-1335,2012.
¿ÆÑд´ÐÂ
[1]ÌÀÓÐÖ¾£¬¸ßÃÀÁᣬÁõÑźì.Ò»ÖÖ¾ßÓÐõ£»ùßßົù²àÁ´µÄ½Ø¶Ì²à¶úËØÑÜÉúÎï¼°ÆäÖƱ¸·½·¨ºÍÓÃ;£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÉêÇëºÅ£º**0.X
[2]ÌÀÓÐÖ¾£¬»ÆÔÊÕ棬ÁõÑźì£¬ÕÅÕÑÊ¥.Ò»ÖÖ¾ßÓÐ2-°±»ùÛÏ´¼²àÁ´µÄ½Ø¶Ì²à¶úËØÑÜÉúÎï¼°ÆäÖƱ¸·½·¨ºÍÓÃ;£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÉêÇëºÅ£º**5.7
[3]ÌÀÓÐÖ¾£¬ÕÅÕÑÊ¥£¬ÁõÑźì.Ò»ÖÖ¾ßÓÐ2-°±»ù±½ÛÏ´¼²àÁ´µÄ½Ø¶Ì²à¶úËØÑÜÉúÎï¼°ÆäÖƱ¸·½·¨ºÍÓÃ;£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÉêÇëºÅ£º**7.5
[4]ÌÀÓÐÖ¾£¬ÍõÎÄÏ棬ÁõÑźì£¬·½Üç.Ò»Àà¾ßÓÐÁòÃѲàÁ´µÄ½Ø¶Ì²à¶úËØ»¯ºÏÎï¼°ÆäÖƱ¸·½·¨ºÍÓÃ;£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÉêÇëºÅ£º**6.9
[5]DeGradoWilliamF.SheppardDean?JoHyunil?ReedNilgunIsikTangYouzhiMcintosh,Joel.Anti-alphavbeta1integrininhibitorssandmethodsofuse.2016,PCTInt.Appl.,WO**
[6]DeGradoWilliamF.SheppardDean?JoHyunil?ReedNilgunIsikTangYouzhi.Anti-alphavbeta1integrincompoundsandmethods.2014,PCTInt.Appl.,WO**
[7]ÌÀÓÐÖ¾£¬ÁõÑźì£¬³ÂÁ¼Öù.Ò»ÖÖÑÎËáÎÖÄáÃîÁÖ³¦ÈÜÐÔ¹ÌÌå·ÖÉ¢Ìå¼°ÆäÖƱ¸·½·¨ÓëÓ¦Óã¬Öйú·¢Ã÷רÀû£¬×¨ÀûÖ¤ÊéºÅ£ºZL**9.X
[8]ÁõÑźì£¬ÌÀÓÐÖ¾.Ò»Öֽض̲à¶úËØÀ࿹ÉúËصÄÖƱ¸·½·¨£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÖ¤ÊéºÅ£ºZL**5.1
[9]ÁõÑźì£¬ÌÀÓÐÖ¾£¬Â潡£¬¸µÏþ»ª.Ò»ÖÖÒÒõ£¼×à­´úл²úÎïÍѶþÑõÒÒõ£¼×à­µÄÖƱ¸·½·¨£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÖ¤ÊéºÅ£ºZL**8.5
[10]ÁõÑźì£¬Â潡£¬ÌÀÓÐÖ¾£¬ÁÎÏþƼ£¬Ëï¼á.Ò»ÖÖ¾ßÓÐßßາàÁ´µÄ½Ø¶Ì²à¶úËØÑÜÉúÎï¼°ÆäÖƱ¸·½·¨ºÍÓÃ;£¬Öйú·¢Ã÷רÀû£¬×¨ÀûÉêÇëºÅ£º**0.X

½ÌÓý±³¾° :
2004Äê9ÔÂ-2009Äê7Ô£¬¼ªÁÖ´óѧ£¬»¯Ñ§Ñ§Ôº£¬Ñо¿Éú/²©Ê¿Ñ§Î»£¬µ¼Ê¦£ºÁõÔÚȺ½ÌÊÚ
2000Äê9ÔÂ-2004Äê7Ô£¬¼ªÁÖ´óѧ£¬»¯Ñ§Ñ§Ôº£¬±¾¿Æ/ѧʿѧλ